Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 4;5(1):2.
doi: 10.1186/s43058-023-00541-0.

A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial

Affiliations

A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial

Masaki Fujiwara et al. Implement Sci Commun. .

Abstract

Background: People with schizophrenia have a lower colorectal screening rate than the general population. A previous study reported an intervention using case management to encourage colorectal cancer screening for patients with schizophrenia in psychiatric outpatient settings. In this feasibility study, we developed provider-level implementation strategies and evaluated the feasibility of conducting a definitive trial in terms of the penetration of the intervention assessed at the patient level. Additionally, we examined the fidelity of strategies to implement the intervention at the provider level in a routine clinical psychiatric setting.

Methods: This was a multicenter, single-arm feasibility study with medical staff at psychiatric hospitals in Japan. The provider-level implementation strategies developed in this study included three key elements (organizing an implementation team appointed by the facility director, interactive assistance using a clear guide that outlines who in the hospital should do what, and developing accessible educational materials) to overcome major barriers to implementation of the intervention and four additional elements (progress monitoring, joint meetings and information sharing among participating sites, adaptation of encouragement methods to specific contexts, and education of on-site staff), with reference to the elements identified in the Expert Recommendations for Implementing Change (ERIC). The feasibility of the strategies was evaluated by the proportion of patients who were eligible for encouragement (patients with schizophrenia aged 40, 50, or 60) who received encouragement. We set the goal of providing encouragement to at least 40% of eligible patients at each site.

Results: Two public and four private psychiatric hospitals in Okayama and Shimane prefectures participated in this study. Regarding fidelity, all elements of the strategies were conducted as planned. Following the procedures in the guide, each team prepared and provided encouragement according to their own facility and region. Penetration, defined as the proportion of eligible patients who received encouragement, ranged from 33.3 to 100%; five of the six facilities achieved the target proportion.

Conclusions: The provider-level implementation strategies to implement encouragement were feasible in terms of penetration of the intervention assessed at the patient level. The results support the feasibility of proceeding with a future definitive trial of these strategies.

Trial registration: jRCT, jRCT1060220026 . Registered on 06/04/2022.

Keywords: Cancer screening; Case management; Implementation; Provider level; Schizophrenia.

PubMed Disclaimer

Conflict of interest statement

M. F.1 has received honoraria for lectures from Mochida. Y. Y. has received honoraria for lectures from Meiji, Sumitomo Pharma, and Lundbeck. N. Y. has received grants from Eisai and Otsuka and has received honoraria for lectures from Eisai, Otsuka, Takeda, MSD, UCB, Viatris, Sumitomo Pharma, and Meiji. M. I. has received grants from Astellas, Eisai, Otsuka, Shionogi, Daiichi Sankyo, Sumitomo Pharma, Takeda, Mitsubishi Tanabe Pharma, Nihon Medi-Physics, Pfizer, Fujifilm, and Mochida and has received honoraria for lectures from EA Pharma, Meiji, MSD, Viatris, Eisai, Otsuka, Sumitomo Pharma, Takeda, Eli Lilly, Nippon Shinyaku, Pfizer, Mochida, Janssen, and Yoshitomiyakuhin. The other authors declare that they have no competing interests.

Similar articles

Cited by

References

    1. Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiat. 2017;4(4):295–301. doi: 10.1016/S2215-0366(17)30078-0. - DOI - PubMed
    1. Zhuo C, Tao R, Jiang R, Lin X, Shao M. Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2017;211(1):7–13. doi: 10.1192/bjp.bp.116.195776. - DOI - PubMed
    1. Ni L, Wu J, Long Y, Tao J, Xu J, Yuan X, et al. Mortality of site-specific cancer in patients with schizophrenia: a systematic review and meta-analysis. BMC Psychiat. 2019;19(1):323. doi: 10.1186/s12888-019-2332-z. - DOI - PMC - PubMed
    1. Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental illness. JAMA Psychiat. 2013;70(2):209–217. doi: 10.1001/jamapsychiatry.2013.278. - DOI - PubMed
    1. World Health Organization . Cancer control: knowledge into action: WHO guide for effective programmes: module 3: early detection. Geneva: World Health Organization; 2007. - PubMed

LinkOut - more resources